Changing the Course of
Cardiovascular Disease

We translate our world-class expertise in cardiovascular signaling pathways into groundbreaking therapeutics for patients.

Acquiring assets where we have unique insights into their use in CV diseases
Discovering new targets and novel drug candidates
Innovating adaptive trial designs to efficiently develop our assets

We translate our world-class expertise in cardiovascular signaling pathways into groundbreaking therapeutics for patients.

Acquiring assets where we have unique insights into their use in CV diseases
Discovering new targets and novel drug candidates
Innovating adaptive trial designs to efficiently develop our assets

A Next Generation Cardiovascular Company

We are addressing the continuing unmet needs of patients with cardiovascular disease through:

Groundbreaking clinical programs

in PDE9 and CaMKII inhibition

Experienced team

of CV experts and industry veterans with track records of success

Strategic portfolio approach

driven by in-house drug discovery and the office of strategy

Foundational partnerships

with key strategics and investors, including a $300 million investment from Bain Capital to support current programs and pipeline growth

Pipeline expansion

in 2022, positioning us for rapid growth across multiple indications

Groundbreaking clinical programs

in PDE9 and CaMKII inhibition

Experienced team

of CV experts and industry veterans with track records of success

Strategic portfolio approach

driven by in-house drug discovery and the office of strategy

Foundational partnerships

with key strategics and investors, including a $300 million investment from Bain Capital to support current programs and pipeline growth

Pipeline expansion

in 2022, positioning us for rapid growth across multiple indications

Man and woman hugging and smiling

We Have Delivered Two Groundbreaking Clinical Programs with upcoming POC Data

Heart Failure: PDE9

PDE9 inhibition presents an opportunity to develop:

  • A foundational new treatment for patients with both types of chronic heart failure
  • A next generation neurohumoral drug, with improved efficacy compared with Entresto®

Arrhythmias and CV Diseases: CaMKII

CaMKII plays a critical role in cardiac function but has been a challenging target to inhibit.

  • First company to successfully take a CaMKII inhibitor into the clinic, initiating a Phase 1 trial in Q3 2022
  • Data positioned to enable rapid development across rare arrhythmias and other CV diseases, including heart failure.
Female researcher looking into microscope

Product Pipeline

PDE9 Inhibitor

CRD-740 - PH 2 / 2B

Heart Failure (HFpEF & HFrEF)

CaMKII Inhibitor

CRD-4730 - PH 1 / 1B

Ph1 (H1 2023); Ph 2 POC Study (Q3 2023)

2nd oral program - IND Enabling

Lead Nomination (Q1 2023)

IV candidate - Discovery

Lead Nomination (H2 2023)

TRPC6 Inhibitor

Preclinical program - Discovery

Lead Optimization (H2 2023)

* CPVT, catecholaminergic polymorphic ventricular tachycardia
**Afib, atrial fibrillation

Contact Us

To request additional information or contact us, please fill out the contact form.

Massachusetts

78 Blanchard Road
Suite 200
Burlington, MA 01803, USA
Info@cardurion.com
617-863-8088

Japan

Cardurion Pharmaceuticals KK
26-1, Muraoka-Higashi 2-chome,
Fujisawa, Kanagawa 251-8555, Japan

Media Contact

Name(Required)
This field is for validation purposes and should be left unchanged.

This site uses cookies and third-party scripts to provide certain services. View Privacy Policy

Skip to content